The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors
Abstract
Targeting neuroendocrine tumors expressing somatostatin receptor subtypes (sst) with radiolabeled somatostatin agonists is an established diagnostic and therapeutic approach in oncology. While agonists readily internalize into tumor cells, permitting accumulation of radioactivity, radiolabeled antagonists do not, and they have not been considered for tumor targeting. The macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) was coupled to two potent somatostatin receptor-selective peptide antagonists [NH 2-CO-c(DCys-Phe-Tyr-DAgl 8(Me,2-naphthoyl)-Lys-Thr-Phe-Cys)-OH (sst 3-ODN-8) and a sst 2-selective antagonist (sst 2-ANT)], for labeling with 111/nat In.111/nat In-DOTA-sst 3-ODN-8 and 111/nat In-DOTA–[4-NO 2-Phe-c(DCys-Tyr-DTrp-Lys-Thr-Cys)-DTyr-NH 2] (111/nat In-DOTA-sst 2-ANT) showed high sst 3- and sst 2-binding affinity, respectively. They did not trigger sst 3 or sst 2 internalization but prevented agonist-stimulated internalization.111 In-DOTA-sst 3-ODN-8 and 111 In-DOTA-sst 2-ANT were injected intravenously into mice bearing sst 3- and sst 2-expressing tumors, and their biodistribution was monitored. In the sst 3-expressing tumors, strong accumulation of 111 In-DOTA-sst 3-ODN-8 was observed, peaking at 1 h with 60% injected radioactivity per gram of tissue and remaining at a high level for >72 h. Excess of sst 3-ODN-8 blocked uptake. As a control, the potent agonist 111 In-DOTA–[1-Nal 3]-octreotide, with strong sst 3-binding and internalization properties showed a much lower and shorter-lasting uptake in sst 3-expressing tumors. Similarly,111 In-DOTA-sst 2-ANT was injected into mice bearing sst 2-expressing tumors. Tumor uptake was considerably higher than with the highly potent sst 2-selective agonist 111 In-diethylenetriaminepentaacetic acid–[Tyr 3,Thr 8]-octreotide (111 In-DTPA-TATE). Scatchard plots showed that antagonists labeled many more sites than agonists. Somatostatin antagonist radiotracers therefore are preferable over agonists for the in vivo targeting of sst 3- or sst 2-expressing tumors. Antagonist radioligands for other peptide receptors need to be evaluated in nuclear oncology as a result of this paradigm shift.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Somatostatin and Its Receptor Family
Patel, Y. C. (1999) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1999.0183 · Cited by 1,648
Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
Reubi, J. C. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0007 · Cited by 1,131
Self-citationReubi, J. C., Schär, J.-C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., & Mäcke, H. R. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050034 · Cited by 1,127
Self-citationReubi, J., Waser, B., Schaer, J.-C., & Laissue, J. A. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100541 · Cited by 657
Self-citationOpportunities in somatostatin research: biological, chemical and therapeutic aspects
Weckbecker, G., Lewis, I., Albert, R., Schmid, H. A., Hoyer, D., & Bruns, C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1255 · Cited by 559
The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance
Hofland, L. J., & Lamberts, S. W. J. (2003) · Endocrine Reviews · doi:10.1210/er.2000-0001 · Cited by 474
Endocytosis and recycling of G protein-coupled receptors
Koenig, J. A., & Edwardson, J. M. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)01091-2 · Cited by 357
Wild, D., Schmitt, J. S., Ginj, M., Mäcke, H. R., Bernard, B. F., Krenning, E., de Jong, M., Wenger, S., & Reubi, J.-C. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1255-5 · Cited by 310
Self-citationParadoxical trafficking and regulation of 5-HT2A receptors by agonists and antagonists
Gray, J. A., & Roth, B. L. (2001) · Brain Research Bulletin · doi:10.1016/s0361-9230(01)00623-2 · Cited by 296
Receptor Targeting for Tumor Localisation and Therapy with Radiopeptides
Heppeler, A., Froidevaux, S., Eberle, A., & Maecke, H. (2000) · Current Medicinal Chemistry · doi:10.2174/0929867003374516 · Cited by 258
de Jong, M., Breeman, W. A., Bakker, W., Kooij, P. P. M., Bernard, B. F., Hofland, L. J., Visser, T. J., Srinivasan, A., Schmidt, M. A., Erion, J. L., et al. (1998) · PubMed · Cited by 209
Self-citationWild, D., Mäcke, H. R., Waser, B., Reubi, J. C., Ginj, M., Rasch, H., Müller-Brand, J., & Hofmann, M. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1697-4 · Cited by 192
Self-citationInternalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.
Cescato, R., Schulz, S., Waser, B., Eltschinger, V., Rivier, J., Wester, H.-J., Culler, M. D., Ginj, M., Liu, Q., Schönbrunn, A., et al. (2006) · PubMed · Cited by 183
Self-citationIdentification and characterization of novel somatostatin antagonists.
Bass, R. T., Buckwalter, B. L., Patel, B. P., Pausch, M. H., Price, L. A., Strnad, J., & Hadcock, J. R. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09370-8 · Cited by 148
Perrin, M. H., Sutton, S. W., Cervini, L. A., Rivier, J., & Vale, W. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38013-9 · Cited by 141
Self-citationGinj, M., Chen, J., Walter, M. A., Eltschinger, V., Reubi, J. C., & Maëcke, H. R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.1136.11.3 · Cited by 101
Self-citationSST3-selective potent peptidic somatostatin receptor antagonists
Reubi, J. C., Schaer, J., Wenger, S., Hoeger, C. A., Érchegyi, J., Waser, B., & Rivier, J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.250483897 · Cited by 100
Self-citationReceptor Signaling and Endocytosis Are Differentially Regulated by Somatostatin Analogs
Liu, Q., Cescato, R., Dewi, D. A., Rivier, J., Reubi, J.-C., & Schönbrunn, A. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.011767 · Cited by 93
Self-citationSleight, A. J., Stam, N. J., Mutel, V., & Vanderheyden, P. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)02122-1 · Cited by 92
Storch, D., Béhé, M. P., Walter, M. A., Chen, J., Powell, P., Mikołajczak, R., & Mäcke, H. R. (2005) · PubMed · Cited by 92
Self-citationGinj, M., Hinni, K., Tschumi, S., Schulz, S., & Maëcke, H. R. (2005) · PubMed · Cited by 66
Self-citationValue of Immunohistochemistry for Somatostatin Receptor Subtype sst2A in Cancer Tissues
Körner, M., Eltschinger, V., Waser, B., Schönbrunn, A., & Reubi, J. C. (2005) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000174013.14569.90 · Cited by 57
Self-citation
Cited by
Wadas, T. J., Wong, E. H., Weisman, G. R., & Anderson, C. J. (2010) · Chemical Reviews · doi:10.1021/cr900325h · Cited by 924
A modeling analysis of the effects of molecular size and binding affinity on tumor targeting
Schmidt, M. M., & Wittrup, K. D. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0195 · Cited by 576
Cancer Treatment Using Peptides: Current Therapies and Future Prospects
Thundimadathil, J. (2012) · Journal of Amino Acids · doi:10.1155/2012/967347 · Cited by 491
Somatostatin receptors: From signaling to clinical practice
Theodoropoulou, M., & Stalla, G. K. (2013) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.07.005 · Cited by 410
Anderson, C. J., & Ferdani, R. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2009.0674 · Cited by 374
Metadata
- Authors
- Ginj, M., Zhang, H., Waser, B., Cescato, R., Wild, D., Wang, X., Erchegyi, J., Rivier, J., Mäcke, H. R., & Reubi, J. C.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2006-10-31
- Volume
- 103
- Issue
- 44
- Pages
- 16436-16441
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2057064048
- Cited by
- 515
- References
- 22
- FWCI
- 13.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.